



SINDUSFARMA



28/03/18 - Conferência: BIOFÁRMACOS  
Da bioprospecção de moléculas produzidas por  
micro-organismos extremófilos às estratégias para  
o desenvolvimento de *biobetters*.



University of São Paulo

**Prof. Dr. Adalberto Pessoa Junior**

Full Professor

Faculty of Pharmaceutical Sciences – University of São Paulo


([peessoajr@usp.br](mailto:peessoajr@usp.br))



# Biotecnologia **FARMACÊUTICA**

*Aspectos sobre aplicação industrial*

Michele Vitolo  
*Coordenador*



**Blucher**


## **Biotecnologia Farmacêutica Aspectos sobre Aplicação Industrial**

Michele Vitolo


2014 — 1ª edição

<http://www.blucher.com.br/livro/detalhes/biotecnologia-farmacutica-175>

# CIÊNCIAS FARMACÊUTICAS E BIOTECNOLOGIA



# Preços de bioprodutos em função de sua concentração no meio inicial



**The global market for bioproducts should reach \$714.6 billion by 2021.**


**SUMMARY FIGURE GLOBAL MARKET FOR BIOPRODUCTS BY CATEGORY,  
2013-2021 (\$ BILLIONS *Estimated values*)**

<b>Bioproduct</b>	<b>Value (US\$)</b>
Antibiotics	10 billions/year
Monoclonal antibodies	10 billions
DNA Probes	1 billion
Insulin	700 millions
Somatostatine	100 millions/year
Transgenic hemoglobin	10 billions

# DESENVOLVIMENTO DE BIOPROCESSOS MICROBIANOS

- Possibilidade de otimização (em até milhares de vezes) da produção.
- **Obtenção de biomoléculas “extremofílicas”.**
- Cultivos microbianos são mais rápidos que “plantas” e “animais”.
- **Processo simples de seleção de microrganismos.**
- Capaz de crescer e originar o produto em culturas de larga escala
- **Possibilita uso de inúmeras fontes de carbono e nitrogênio**
- Relação área/volume favorável  $\Rightarrow$  rápida absorção de nutrientes, alta velocidade de síntese e metabolismo
- **Diversidade metabólica**
- Adaptabilidade a distintos ambientes e condições de crescimento
- **Capacidade de sintetizar enantiômeros específicos**
- Tecnologias “*limpas*”

# Processo Genérico de Produção de Biofármacos



# Antártica – Ambiente Extremo Pode ser fonte de Biofármacos?

**PROTEASES**



**ASPARAGINASES**




# Enzimas adaptadas ao frio


- Podem catalisar reações a temperaturas baixas e moderadas (< 40°C) de forma mais eficiente com poucas reações químicas indesejáveis que ocorrem a altas temperaturas.
- **Maior Resistência a solventes orgânicos e detergentes.**
- Redução do gasto energético associados às etapas de aquecimento no processo produtivo.
- **Maior estabilidade a estresses ambientais.**

São até 10 vezes mais ativas a temperaturas baixas/moderadas do que as homólogas mesofílicas

São inativadas a temperaturas maiores do que as ótimas para catálise




Feller & Gerday (2003) Nature, 1:200-208



# Extremophile Producers of Biopharmaceuticals


## PROTEASES - PROPERTIES E APPLICATIONS



**PLANTS:** Papain, Bromelain, Ficin



**ANIMALS:** Trypsin, chymotrypsin, pepsin, renin



**Microorganisms:** acidic, neutral and alkaline

INDUSTRY OF DETERGENTS

FOOD INDUSTRY

PHARMACEUTICAL INDUSTRY

FINE CHEMISTRY

WASTE TREATMENT

LEATHER PROCESSING

COSMETICS

# PROTEASES

digestive aid



PAPAIN gel (2%)  
Healing - debriding - antibacterial and  
anti-inflammatory



# ISOLATION OF FUNGI FROM ANTARCTIC CONTINENT

**SEA SPONGE**



**STAR SEA**



**SEAWEED**



**ASCIDIA**



**SNAIL**



**LICHEN**




**SEA URCHIN**



**NACELLA**



**SALPA**




**ISOPODE**





**SOIL  
PENGUINS**




# Fungi Isolation - Methodology



Samples collected in sterile saline




Serial dilution in sterile saline




Isolation by direct plating and serial dilution.

Antibiotic + medium


# Isolation of producers of **Proteases**: yeasts




# YEAST SUBMERGED CULTIVATION



# CULTIVATION OF THE ISOLATED YEASTS – THE POSITIVE-PROTEASES










Diagrama de um fermentador, ilustrando a construção e os dispositivos para a aeração e controle do processo.

# PROTEASE PRODUCTION BY RHODOTORULA MUCILAGINOSA



Inoculum



Supernatant: proteases



Pellet: cells

New possibilities



carotenoids





lipids

*Rhodotorula* can store more than 50% in lipids

# PROTEASE PURIFICATION - *Rhodotorula mucilaginosa* L07

## Ionic Exchange: CM-Sepharose



**Purification Yield: 48.5%**  
**Purification Factor: 12.9 times**


## RELEVANT COMMENTS

- **14,14% of the isolated yeasts from Antarctica were **protease-positive****
- **Protease from *R. mucilaginosa* L07 – acidic characteristic – **medical potential (as debriding, antibacterial and anti-inflammatory actions) and cosmetic potential (skin lighter and peeling).****
- **Highly stable.**

# **L-Asparaginase**

**Biofármaco empregado no tratamento  
de Leucemia Linfoide Aguda - LLA**

# Source of L-asparaginase



# Where are we looking for new Asparaginases?



**Antarctic Continent (Extremophile Environment - cold and dry)**




**Atlantic Ocean - North coast of the State of São Paulo (Extremophile environment - high pressure and saline concentration)**



**Coconut plantation - State of Paraíba - (dry environment - Biome little explored)**



**Caatinga - State of Pernambuco - (dry environment - Bioma little explored)**




**“Cerrado” - (dry environment - little explored biome)**

**Results: we found hundreds of fungi producing L-asparaginase, but to date none of them presented characteristics suitable for a biopharmaceutical**




# Initial identification of fungi producers of L-asparaginase

## *Initial Screening – two different methodologies*



Red phenol	
<i>pH below 6.6</i>	<i>pH above 8,0</i>
<b>Yellow</b>	<b>red</b>




Bromothymol blue	
<i>pH below 6.6</i>	<i>pH above 7,6</i>
<b>Yellow</b>	<b>blue</b>

# Examples: Plates with phenol red


Cepa 3




Cepa 79



Cepa 20




# Examples: Plates with bromothymol blue




**L-ASPARAGINASE PRODUCTION BY FILAMENTOUS FUNGI  
ISOLATED FROM THE BRAZILIAN BIOME (CERRADO)**

# FUNGI SELECTED AS L-ASPARAGINASE WITH LOW GLUTAMINASE ACTIVITY


*Penicillium sizovae*  
(2DSST1)



*Fusarium proliferatum*  
(DCFS10)



*Penicillium decumbens*  
(DCFS6)






Figure 1. Growth curves and L-asparaginase production of fungi 2DSST1 (A), DCFS10 (B) and DCFS6 (C). Line (—) biomass concentration and line (...) L-asparaginase activity.

# Caracterização de enzimas de interesse industrial

**Avaliação das Atividades enzimáticas**


**Avaliação de Inibidores Enzimáticos**

**Estabilidade ao pH e temperatura**

**Temperatura e pH ótimos**




**Efeito de Sais e de Surfactantes**

**Massa Molecular e Ponto Isoelétrico**




# Avaliação de diferentes fatores na produção de enzimas de interesse industrial e/ou ambiental

## Desenho experimental






# L-Asparaginase from Antarctica




**Search for extracellular L-ASNase with high specificity for L-asparagine and low activity of L-glutamine from Antarctic Continent can generate a new enzyme with higher stability for the production of a new biopharmaceutical.**

# Antarctic



## SDS-PAGE




(3) and (4) L-ASPase I fractions obtained by Size exclusion chromatography.

# **CULTIVO EM BIORREATOR DE BANCADA**


**Avaliar parâmetros importantes para o escalonamento do processo**

# 3L BIORREACTOR PRODUCTION



← **BATCH 1: Growth phase with Glycerol 10 g/L, 30 °C.**


Variation of cell concentration (●), dissolved oxygen (■) and periplasmic ASNase activity (▲) against time for recombinant *P. pastoris* grown in 500 rpm and 1 vvm, inducing phase: 3% (v/v) of methanol, 20 °C.



← **BATCH 2: Growth phase with Glycerol 40 g/L, 30°C.**

# Asparaginase from recombinant *E. coli*

## Extracellular ASNase secretion – new method



SDS-PAGE – extracellular extract from *E. coli* BL21 with addition of glycine and n-dodecane

Cultivation time: 0 h; (2) 4 h; (3) 8 h; (4) 12 h; (5) 16 h; (6) 20 h; (7) 24 h. (8) 1 mg/mL of commercial ASNase.

# Patent Application



## Anotação de transferência de titular

Número do Processo: BR 10 2016 024702 0

### Dados do Interessado

---

Interessado 1 de 2

Nome ou Razão Social: UNIVERSIDADE DE SÃO PAULO - USP

## Low Molecular Mass ASNase from *E. coli*

sob nº 63.025.530/0001-04, titular do pedido de patente sob o título: "Método de obtenção de L-Asparaginase recombinante de baixa massa molar, L-Asparaginase recombinante e uso da mesma", identificado pelo nº BR 10 2016 024702-0, depositado em 21/10/2016, neste ato, com fulcro no inciso I do artigo 6º da Portaria GR nº 6.651, de



## Comunicação de Criação

ID:	CC-PI-2017-0034
Título Provisório:	NOVA ENZIMA L-ASPARAGINASE DE BACTERIA DICKEYA CHRYSANTHEMI, PRODUZIDA EM SISTEMA DE EXPRESSÃO EUCARIOTO
Modalidade de Proteção:	Patente
Houve divulgação do conteúdo da criação?	<input type="checkbox"/> Não houve divulgação do conteúdo total ou parcial dessa criação. [ ]
Existe ex criação?	<input checked="" type="checkbox"/> <b>ASNase from <i>Pichia pastoris</i> with human glycosylation pattern</b>
A pesquisa foi desenvolvida em cooperação com instituições externas?	<input type="checkbox"/> [Anexo 2 - Quadro Resumo]

# OBRIGADO !!!

**FAPESP – Thematic Project 2013/08617-7**

**CAPES – Scholarship of some students**



**Adalberto Pessoa Junior – [pessoajr@usp.br](mailto:pessoajr@usp.br)**



**Perguntas???**

**Preguntas???**

**Questions???**

